Patient Guide: A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at 17 participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTNCT05899049
Status: ACTIVE_NOT_RECRUITING
Condition: Carcinoma, Renal Cell
Phase: PHASE3

Find a Study Location Near You

This study is available at 17 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • Beijing, Beijing Municipality
  • Chongqing, Chongqing Municipality
  • Guangzhou, Guangdong
  • • And 14 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily